SLIM - The Obesity ETF

Invest in the Battle Against Obesity

NAV: $25.48

1-Day Change: $-0.06 (-0.23%)

As of market close 5/26/17

    Pricing Data (As of market close 05/26/17)
    Closing Market Price$24.32
    Bid/Ask Midpoint$24.95
    Day High$24.32
    Day Low$24.27
    Trading Volume (Shares)10
    Premium/Discount (%)-2.08%
    Shares Outstanding.10M
    Yield & Expenses

    Distribution Yield at NAV
    (As of 03/31/2017)

    30 Day SEC Yield
    (As of 4/30/17)
    Distribution FrequencyQuarterly
    Total Net Assets
    (As of 5/26/17)
    Annual Expense Ratio
    GROSS 0.50%
    NET 0.50%
    Fund Details
    Inception Date 06/08/2016
    CUSIP 47103U506
    Morningstar (As of 04/30/2017)
    US Fund Health
    Intraday Value (IOPV) SLIMIV
    Exchange NASDAQ
    Index Ticker SLIMID
    Primary Benchmark Solactive Obesity Index
    Index Provider Solactive AG

    ETF Objective

    The Obesity ETF (SLIM) seeks investment results that correspond generally, before fees and expenses, to the performance of the Solactive Obesity Index.


    Thematic ETFs provide investors with the opportunity to invest in companies that may benefit from the transformational forces changing our future. The Obesity ETF seeks exposure to companies globally that could benefit as they fight the global obesity epidemic, including: biotechnology, pharmaceutical, healthcare and medical device companies whose business is focused on obesity and obesity related disease, including diabetes, high blood pressure, cholesterol, heart disease, stroke and sleep apnea, and companies focused on weight loss programs and supplements, and plus sized apparel.

    Why Invest in SLIM

    Humans are Getting Heavier

    Worldwide, more than 10% of men and some 14% of women are now classified as obese; those numbers are predicted to climb to 18% of men and 21% of women by 2025.

    Source: World Health Organization, Washington University School of Medicine, NCD Risk Factor Collaboration 4/2016

    Rising Costs Spurring Action

    As obesity and overweight levels rise, so do the enormous direct and indirect medical expenditures for treatment and prevention which globally are estimated at $2 trillion annually – creating increased pressure to tackle the issue.

    Source: National Center for Weight & Wellness at George Washington University and the McKinsey Global Institute 4/2015.

    Targeted Thematic Exposure

    The strategy provides investors with the opportunity to invest in companies globally that could benefit as they fight the global obesity epidemic.